Cell biology - Lessons in rational drug design for protein kinases

被引：14

作者：

Ahn, NG ^{[1
]}

Resing, KA ^{[1
]}

机构：

[1] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA

来源：

SCIENCE | 2005年 / 308卷 / 5726期

关键词：

D O I：

10.1126/science.1113707

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

[No abstract available]

引用

页码：1266 / 1267

页数：2

共 8 条

[1] Bridges AJ, 1999, CURR MED CHEM, V6, P825
[2] Structural bioinformatics-based design of selective, irreversible kinase inhibitors
Cohen, MS
Zhang, C
Shokat, KM
Taunton, J
[J]. SCIENCE, 2005, 308 (5726) : 1318 - 1321
[3] The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M
Buchdunger, E
Druker, BJ
[J]. BLOOD, 2005, 105 (07) : 2640 - 2653
[4] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Gorre, ME
Mohammed, M
Ellwood, K
Hsu, N
Paquette, R
Rao, PN
Sawyers, CL
[J]. SCIENCE, 2001, 293 (5531) : 876 - 880
[5] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
Kobayashi, S
Boggon, TJ
Dayaram, T
Janne, PA
Kocher, O
Meyerson, M
Johnson, BE
Eck, MJ
Tenen, DG
Halmos, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) : 786 - 792
[6] Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y
Bishop, A
Witucki, L
Kraybill, B
Shimizu, E
Tsien, J
Ubersax, J
Blethrow, J
Morgan, DO
Shokat, KM
[J]. CHEMISTRY & BIOLOGY, 1999, 6 (09): : 671 - 678
[7] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Pao, W
Miller, VA
Politi, KA
Riely, GJ
Somwar, R
Zakowski, MF
Kris, MG
Varmus, H
[J]. PLOS MEDICINE, 2005, 2 (03) : 225 - 235
[8] Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
Pao, W
Miller, VA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2556 - 2568

← 1 →